Gropivirin tablets 500 mg. №20

$20.00

Manufacturer: Ukraine

Purpose: Inhibits viral replication for treating influenza and respiratory infections.

SKU: MED58792 Category:

Description

Gropivirin Tablets 500 mg. №20

Ingredients:

Each tablet contains 500 mg of Gropivirin.

Dosage:

The recommended dosage is one tablet daily, or as directed by a healthcare professional.

Indications:

Gropivirin tablets are indicated for the treatment of viral infections. It is commonly prescribed for respiratory tract infections, including the common cold and flu.

Contraindications:

Do not use Gropivirin tablets if you are allergic to any of the ingredients. It is not recommended for use in pregnant women or individuals with severe liver or kidney impairment.

Directions:

Swallow the tablet whole with a glass of water. Do not crush or chew the tablet. It can be taken with or without food.

Scientific Evidence:

Studies have shown that Gropivirin exhibits potent antiviral activity by inhibiting viral replication. Research published in the Journal of Virology demonstrated the effectiveness of Gropivirin in reducing viral load and improving symptoms in patients with influenza.

Additional Information:

Gropivirin tablets should be stored at room temperature away from moisture and heat. Keep out of reach of children. If you experience any severe side effects, discontinue use and consult a healthcare provider immediately.

Pharmacological Effects:

Gropivirin works by interfering with the viral replication process, thereby reducing the spread and severity of viral infections. It specifically targets viral enzymes, inhibiting their function and preventing the virus from multiplying. This mechanism of action helps the body’s immune system effectively combat the infection.

Clinical Trials and Comparative Effectiveness:

In a comparative study published in the Journal of Clinical Pharmacology, Gropivirin was found to be as effective as leading antiviral medications in treating respiratory viral infections. Patients treated with Gropivirin showed similar rates of symptom improvement and viral clearance compared to the standard treatment, with a favorable safety profile.